Isatuximab

04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
3:11
Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma
Enrique Ocio
1:46
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
Niels van de Donk
2:41
Isatuximab: a ‘next-generation monoclonal antibody’
Paul Richardson
1:07
Promising results for isatuximab with carfilzomib in R/R MM
Ajai Chari
1:30
VCDI for multiple myeloma: an update
Enrique Ocio
3:34
How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau
2:20
Promising novel treatments in multiple myeloma
Paul Richardson
1:45
Isatuximab and pomalidomide for the treatment of MM
Joseph Mikhael
1:03
The importance of anti-CD38 monoclonal antibodies for multiple myeloma
Rafael Fonseca
4:11
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
Joseph Mikhael
3:58
The impact of new drugs and the changing role of transplants in multiple myeloma
Paul Richardson
2:20
Isatuximab for multiple myeloma – promising results and next steps
Thomas Martin
1:57
New therapies in multiple myeloma
Rafael Fonseca
2:10
Overview of a Phase II clinical trial of isatuximab
Joseph Mikhael
9:21
Phase Ib dose escalation trial of SAR650984 improves outcomes in relapsed or refractory myeloma
Thomas Martin
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals